Joining Forces to Improve the Lives of Patients

We are pushing the bounds of what is possible in developing treatments for serious diseases with unmet needs, but we cannot do this alone. Forging strategic partnerships with companies, universities and research institutions helps us realize the full potential of our science.

Additionally, we provide our investigational products and/or financial support for independent research by third parties in therapeutic areas of interest. We ensure that submitted requests for Investigator-Initiated Research are reviewed and, if approved, conducted and funded in a standardized and consistent manner, in compliance with all applicable legal and ethical standards and obligations. If you have questions about investigator-initiated research or are interested in submitting a research proposal, please contact us at iir.incyte.com.

In order to share knowledge, resources and ideas that may best benefit patients, we are committed to alliances, partnerships and collaborations with major universities and other companies to bring additional discovery platforms and therapeutics forward. We also evaluate assets that have the potential to expand our pipeline, geographic reach or technological base. We enjoy working with like-minded partners who want to join forces to improve the lives of patients.

To contact our Business Development team, please e-mail bd@incyte.com.

SOME OF OUR CURRENT COLLABORATIONS

Agenus - Logo of Agenus Inc.
Agenus Inc.

Antibody development collaboration

Biotheryx, Inc. logo
Biotheryx, Inc.

Discovery collaboration for oncology targeted protein degraders

Cellenkos logo
Cellenkos

Global development collaboration

China Medical System logo
China Medical System Holdings Limited

Multi-product dermatology development and commercialization in Asia

InnoCare logo
InnoCare Pharma Limited

Oncology commercialization collaboration in Asia

Logo of Innovent
Innovent Biologics (HK) Limited

Commercialization collaboration in Asia

Lilly - Logo of Eli Lilly and Company
Eli Lilly and Company

JAK inhibitor anti-inflammatory diseases and COVID-19 collaboration

MACROGENICS - Logo of Macrogenics, Inc.
MacroGenics, Inc.

Monoclonal antibody development collaboration

Maruho logo
Maruho Co., Ltd.

Topical JAK inhibitor development and commercialization collaboration in Japan

Merus - Logo of Merus N.V.
Merus N.V.

Bispecific antibody development collaboration

Novartis - Logo of Novartis International Pharmaceutical Ltd.
Novartis International Pharmaceutical Ltd.

Oncology, hematology and graft-versus-host disease collaboration

Syndax logo
Syndax Pharmaceuticals, Inc.

Monoclonal antibody development and commercialization collaboration